Home » TEVA REPORTS TENTATIVE APPROVAL OF RABEPRAZOLE TABLETS
TEVA REPORTS TENTATIVE APPROVAL OF RABEPRAZOLE TABLETS
Teva has announced that the FDA has granted tentative approval for the company's abbreviated new drug application for 20-mg Rabeprazole sodium delayed-release tablets.
Upon final approval, the drug will be the generic equivalent of Eisai's acid pump inhibitor Aciphex tablets.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May